Gilead Sciences vs Moderna: Stock Performance Comparison 2026

The Gilead Sciences (GILD) vs Moderna comparison in 2026 often comes down to Gilead Sciences (GILD) appealing to income-focused, stability-seeking investors, while Moderna (MRNA) tends to suit traders comfortable with higher volatility and pipeline-driven swings. Both sit at the center of biotech innovation, but they reach that spot in very different ways: one through established HIV and antiviral cash flows, the other through mRNA vaccine and therapy bets that may take years to fully prove out. Comparing their stock performance, risk profiles, and growth paths helps investors decide which style better matches their own time horizon and risk tolerance.

Summary

Is Gilead Sciences (GILD) a Safer Biotech Stock Than High-Growth Peers in 2026?

Investment Profile

Gilead Sciences (GILD) is the cash-generating, dividend-paying incumbent in the Gilead Sciences vs Moderna matchup, trading more on durable HIV earnings than on high-risk vaccine breakthroughs. Gilead generates $29.4B in annual revenue with modest 2.4% year-over-year growth, but backs this with $9.5B of free cash flow and a 2.6% dividend yield, offering a steadier profile than a single-platform mRNA player. At a trailing P/E of 17.1 and forward P/E of 13.1, the stock trades at an earnings multiple that reflects both its HIV strength and oncology execution risk.

The company’s roughly 70% U.S. HIV share, supported by Biktarvy patents out to 2036, helps underpin Gilead’s $156.3B market cap and funds diversification into oncology. Shares trade below their 52-week high of $157.29, with a +4.1% YTD return that lags more volatile innovation-driven names but may appeal to investors prioritizing income and visibility. Compared with Moderna, Gilead leans on a broad commercial base and dividends rather than a single emerging technology, but faces its own binary risks from Trodelvy, CAR-T programs, and key FDA decisions that could swing sentiment.

Key Catalysts

• Trodelvy label expansions: Late-stage Trodelvy trials such as ASCENT-03/04 in additional breast cancer settings could broaden its use and shift Gilead’s story from mainly HIV toward a more balanced oncology profile.
• CAR-T pipeline readouts: Upcoming data from CAR-T programs like ZUMA-22/23 and the iMMagine series in lymphoma and multiple myeloma may create meaningful sentiment swings if they show durable responses in hard-to-treat cancers.
• Next-generation HIV prevention: The Phase 3 PURPOSE 365 study of lenacapavir for PrEP, along with possible bictegravir/lenacapavir oral combinations, could extend Gilead’s HIV leadership into long-acting prevention and new treatment formats.
• Projected FCF ramp post-IPR&D: Consensus expectations for free cash flow to rebound sharply by 2027, with estimates around $13.3B as one-time R&D charges fade, may unlock more room for dividends, buybacks, or incremental business development.
• Lower deal overhang: Management’s guidance that large acquisitions are "less likely" in the near term reduces fear of dilutive mega-deals and may allow investors to focus more on organic growth and pipeline milestones.

Strengths

• Stable revenue base: Gilead generates $29.4B in annual revenue with 2.4% year-over-year growth, providing a large and relatively steady foundation compared with many biotech peers that rely on a few early-stage assets.
• Strong cash generation: About $9.5B in free cash flow each year gives Gilead substantial room to fund R&D, support its dividend, and consider targeted deals without stressing the balance sheet.
• Dominant HIV franchise: Roughly 70% U.S. market share for Biktarvy, with U.S. exclusivity extended to 2036, supports long-lasting cash flows that help offset the risk of setbacks in newer oncology programs.
• Income component: A 2.6% dividend yield, backed by significant free cash flow, may appeal to investors looking for current income alongside exposure to biopharma innovation.
• Valuation with some cushion: A forward P/E of 13.1, below the trailing 17.1, suggests the market expects earnings to grow, which may provide some downside cushion if growth modestly underperforms.

Risks and Challenges

• HIV concentration risk: Heavy reliance on HIV drugs means pricing pressure, changing treatment guidelines, or faster-than-expected generic competition outside the U.S. could have an outsized impact on overall revenue.
• Competitive HIV landscape: Rivals such as ViiV Healthcare and future generics may gradually chip away at Gilead’s HIV share and pricing power, even with Biktarvy’s extended U.S. patent protection.
• Anito-cel FDA decision risk: A key FDA decision on anito-cel expected in December represents a binary event where an unfavorable outcome could remove a major near-term oncology catalyst and pressure the stock.
• Trodelvy trial outcome risk: If Trodelvy does not show positive results in first-line triple-negative breast cancer, one of Gilead’s main oncology growth pillars could weaken, potentially dampening enthusiasm for its diversification strategy.
• Pipeline execution uncertainty: Delays, negative data, or stricter-than-expected regulatory reviews across Trodelvy, CAR-T programs, and other late-stage studies could push out expected oncology revenues and leave Gilead more dependent on HIV longer than planned.

Why Is Moderna (MRNA) a High-Risk High-Reward Biotech Stock in 2026?

Investment Profile

Moderna (MRNA) is the higher-risk, higher-upside growth stock in the Gilead Sciences vs Moderna matchup, trading much more on future pipeline potential than on current earnings power. Moderna generated about $1.9B in annual revenue, with EPS at -$8.14 and free cash flow around -$2.1B, highlighting how dependent the story is on new product launches rather than established cash flows. By contrast, Gilead typically brings steadier profits and dividends, so investors comparing the two are weighing stability against a more speculative platform bet.

The market currently values Moderna at roughly $19.7B, with a forward P/E of -11.8 that reflects expected losses rather than near-term profitability. Despite that, the stock has surged about 60.9% year-to-date and trades between a 52-week low of $22.28 and a recent high of $59.55, showing how sensitive sentiment is to pipeline news and guidance. Moderna’s late-stage mRNA programs in flu (mRNA-1010) and oncology could reshape revenue over 2025–2028, but setbacks on those assets would likely hit Moderna much harder than Gilead, which has a more diversified, cash-generative portfolio.

Compared with Gilead’s mature antiviral and oncology franchises, Moderna is still in transition from COVID-driven sales to a broader respiratory and cancer vaccine portfolio. Management is guiding to modest revenue growth in 2026 and is targeting cash breakeven by 2028, which, if achieved, could gradually narrow the gap with Gilead on financial stability. Until then, Moderna may appeal more to investors who are comfortable with clinical and regulatory risk in exchange for platform upside, while Gilead may suit those who prioritize current earnings and lower volatility.

Key Catalysts

• Flu vaccine approval decision: An FDA decision for the mRNA-1010 flu vaccine on August 5 is a key potential catalyst that could open a new annual respiratory revenue stream if approved.
• Cancer vaccine trial readouts: Phase II/III data for the personalized cancer vaccine mRNA-4157/Intismeran in combination with Keytruda could significantly influence Moderna’s long-term oncology narrative and valuation.
• Cluster of 2026 data events: Multiple respiratory and oncology trial readouts expected around 2026 may either validate the mRNA platform beyond COVID or raise new questions, likely driving stock volatility.
• Turnaround and margin story: The plan to reach cash breakeven by 2028 via expense discipline and new launches provides a medium-term turnaround narrative that investors will track against each quarterly update.

Strengths

• Scaled mRNA platform: A broad mRNA pipeline, including late-stage programs like the mRNA-1010 flu vaccine and personalized cancer vaccine mRNA-4157/Intismeran, gives Moderna multiple shots on goal beyond COVID boosters.
• Proven commercial and manufacturing experience: Prior Spikevax commercialization built global mRNA manufacturing and distribution capabilities that can be reused for new respiratory and oncology products.
• Near-term growth outlook: Management is guiding to up to about 10% revenue growth in 2026, mainly from respiratory vaccines, which may help stabilize revenue after a sharp COVID comedown.
• Cost-reduction roadmap: Planned cuts to cost of sales, R&D, and SG&A are part of a strategy to reach cash breakeven by 2028, which could narrow losses over time.

Risks and Challenges

• Shrinking revenue and cash burn: Revenue of about $1.9B with a roughly 39.9% year-over-year decline and free cash flow around -$2.1B show Moderna is still in a heavy investment phase with no current earnings support.
• Ongoing losses and no earnings multiple: EPS of -$8.14 and a negative forward P/E of -11.8 mean the stock trades mostly on expectations for future products rather than on current profits, increasing downside if the pipeline disappoints.
• High binary trial risk: Late-stage programs like mRNA-1010 and mRNA-4157/Intismeran carry binary clinical and regulatory risk, where negative data or setbacks could significantly cut expected future cash flows.
• Legal and IP overhang: Ongoing and potential new COVID-era litigation, including intellectual property and product claims, may add to costs and create earnings volatility beyond current guidance.
• Crowded competitive landscape: Established vaccine makers and other mRNA developers are pushing into flu, RSV, and oncology, which may limit Moderna’s pricing power and market share even if its products gain approval.
• Operational scaling challenges: Scaling manufacturing and commercial infrastructure for several new respiratory and oncology launches at once could lead to delays, supply issues, or higher-than-planned SG&A, pressuring the turnaround story.

Gilead Sciences vs Moderna: Side-by-Side Comparison

What Are the Biggest Shared Risks for Gilead Sciences vs Moderna Investors in 2026?

The key shared risks for Gilead Sciences vs Moderna center on drug-pricing pressure, tougher regulation, and the boom-bust nature of biotech R&D. Both companies depend on high-priced specialty medicines, so any broad move by the U.S. or European governments to clamp down on drug prices could hit revenue and margins at the same time. Expansion of U.S. price-negotiation rules, stricter limits on annual price increases, or new reference-pricing schemes abroad would likely compress returns on both existing products and future launches.

Biotech as a whole also faces rising regulatory and funding uncertainty. If drug-safety rules tighten or approval standards rise after a high-profile safety event, development timelines for both companies could get longer and more expensive. A shift in investor sentiment away from high-risk drug developers - whether due to higher interest rates, a recession, or a market rotation into “safer” sectors - could hurt valuations for Gilead and Moderna at the same time, even if their pipelines stay intact.

Scientific and competitive risks overlap as well. Both rely on a constant flow of new or improved therapies to offset patent losses and keep revenue growing. If rapid advances in competing technologies - other viral platforms, cell therapies, or next-generation mRNA - change treatment standards, both companies may need heavier R&D and partnership spending just to defend market share. That combination of pricing pressure, regulatory uncertainty, and shifting science can make earnings and stock performance more volatile for both names than many other large-cap sectors.

Gilead Sciences vs Moderna: Which Stock Looks Stronger in 2026?

• Gilead Sciences vs Moderna in 2026 tilts toward Gilead for stability, while Moderna offers higher risk - reward with a smaller $19.7B valuation and faster moves.
• On valuation and size, Gilead leads with a $156.3B market cap and more mature profile, versus Moderna’s $19.7B smaller-cap positioning.
• For momentum, Moderna screens stronger with a 60.9% YTD gain, far outpacing Gilead’s more modest 4.1% rise.
• On defensive characteristics, Gilead appears stronger, with slower stock swings implied by its steadier 4.1% year-to-date performance.
• For upside potential tied to sentiment shifts, Moderna tilts higher, as recent 60.9% YTD performance shows the market is more aggressively repricing its prospects.

Frequently Asked Questions

How does Gilead Sciences’ market cap compare to Moderna’s in 2026?

As of June 2026, Gilead Sciences has a market cap of about $156.3 billion, while Moderna’s market cap stands near $19.7 billion. This means Gilead’s equity value is roughly eight times larger than Moderna’s.

Which is more profitable in 2026, Gilead Sciences or Moderna?

Gilead Sciences is currently profitable, with earnings per share (EPS) of $7.35 and free cash flow of $9.5 billion. Moderna is loss-making, with EPS of -$8.14 and free cash flow of -$2.1 billion, reflecting ongoing investment and lower revenue.

How do Gilead Sciences and Moderna differ on revenue size and growth in 2026?

Gilead Sciences generates annual revenue of $29.4 billion with year-over-year growth of 2.4%. Moderna reports much smaller annual revenue of $1.9 billion and a revenue decline of 39.9% year over year.

What is the 2026 year-to-date stock performance for Gilead Sciences vs Moderna?

By June 2026, Gilead Sciences shows a year-to-date return of 4.1%. Over the same period, Moderna’s year-to-date return is 60.9%, indicating much stronger recent share price momentum despite weaker current earnings.

Does Gilead Sciences or Moderna pay a dividend in 2026, and how does valuation compare?

Gilead Sciences offers a dividend yield of 2.6% and trades at a trailing P/E of 17.1 with a forward P/E of 13.1. Moderna does not show a dividend yield and has a negative forward P/E of -11.8, reflecting expectations of continued losses in the near term.

Disclaimer: This article is for informational purposes only and does not constitute financial advice. Past performance is not indicative of future results. Always conduct your own research or consult a licensed financial advisor before making investment decisions.